DALLAS / Mar 28, 2024 / Business Wire / Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2023.
“We are now at the halfway point of Project Greenfield, our three-year strategic plan to unlock the company’s potential and provide a path to profitability, and the results of this focus are unmistakable,” said Stan Jacot, president and CEO. “Arcadia has significantly improved quality of revenues and has now delivered two straight years of gross profit growth for the first time in its history. SG&A expenses have declined for two straight years and are at their lowest level since 2019.
“The foundation we have laid over the past two years provides optimism for even stronger results in 2024. GoodWheatTM is now in three categories with pasta, pancakes and mac & cheese, and garnering national attention. Zola® coconut water is leveraging innovation to expand distribution and is anticipating double-digit growth in 2024. We have right sized the organization and streamlined our cost structure in order to extend our runway. And finally, we remain focused on adjacent acquisitions as well as monetizing our IP,” Jacot said.
2023 Key Operating and Business Highlights
Recent Highlights
Arcadia Biosciences, Inc. | |||||||||||||||||||||||
| Three months ended Dec 31 |
| Twelve months ended Dec 31 | ||||||||||||||||||||
| 2023 |
| 2022 |
| Favorable/ |
|
| 2023 |
| 2022 |
| Favorable/ | |||||||||||
| $ | % | $ | % | |||||||||||||||||||
Total Revenues | 1,170 |
| 744 |
| 426 | 57 | % |
| 5,330 |
| 7,418 |
| (2,088 | ) | (28 | %) | |||||||
Total Operating Expenses | 4,534 |
| 5,402 |
| 868 | 16 | % |
| 19,268 |
| 21,425 |
| 2,157 |
| 10 | % | |||||||
Loss From Continuing Operations | (3,364 | ) | (4,658 | ) | 1,294 | 28 | % |
| (13,938 | ) | (14,007 | ) | 69 |
| 0 | % | |||||||
Net Loss Attributable to Common Stockholders | (2,853 | ) | (4,244 | ) | 1,391 | 33 | % | (13,981 | ) | (15,376 | ) | 1,395 |
| 9 | % |
Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former body care brands as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise.
More detailed financial statements are included in the Form 10-K filed today, available in the Investors section of the company’s website under SEC Filings.
Revenues
Revenues in the fourth quarter of 2023 increased 57% to $1.2 million compared to the same period in 2022 driven by higher GoodWheat and GLA revenues.
Revenues decreased $2.1 million during 2023 compared 2022. Revenues during 2022 included approximately $1.8 million in sales of GoodWheat grain as well as $0.9 million in one-time license revenue related to the sale of Verdeca.
Operating Expenses
Operating expenses decreased $868,000 during the fourth quarter of 2023 compared to the same period in 2022 primarily driven by a decrease in cost of revenues and selling, general and administrative (SG&A) expenses in 2023. Cost of revenues in the fourth quarter of 2022 included higher inventory write downs. The decrease in SG&A was primarily related to lower employee costs in 2023.
Operating expenses decreased $2.1 million during 2023 compared to 2022 primarily driven by a decrease in cost of revenues and SG&A. Cost of revenues in 2022 included grain sold at cost and higher inventory write-downs. The decrease in SG&A was primarily related to lower employee costs in 2023.
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders for the fourth quarter of 2023 was $2.8 million, or $2.10 per share, a $1.4 million improvement from the $4.2 million, or $6.31 per share, net loss for the fourth quarter of 2022. The improvement in net loss attributable to common stockholders for the fourth quarter of 2023 compared to the same period in 2022 was primarily driven by the reduction in operating expenses.
Net loss attributable to common stockholders for 2023 was $14.0 million, or $11.30 per share, a $1.4 million improvement from the $15.4 million, or $25.65 per share, net loss for 2022. The improvement in net loss attributable to common stockholders for 2023 compared to 2022 was primarily driven by the reduction in operating expenses. The impact of the March 2023 financing had a minimal effect during 2023 as a $6.1 million valuation loss was largely offset by a non-cash gain of $6.5 million related to the change in the fair value of the common stock warrant and option liabilities compared to a non-cash gain of $3.2 million during 2022. Additionally, 2023 included a net loss from the discontinued body care brands of $821,000 compared to $4.8 million during 2022.
Conference Call and Webcast
The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) today, March 28, to discuss fourth-quarter and year-end results and the year’s key strategic achievements. Interested participants can join the conference call using the following options:
Following completion of the call, a recorded replay will be available on the company’s investor website.
About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating crops to provide high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make every body feel good. The company’s food and beverage products include GoodWheat™ pasta, pancake mixes and mac & cheese and Zola® coconut water. For more information, visit www.arcadiabio.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about the company and its products, including statements relating to the company’s growth, cash position, operating costs, financial performance, commercialization of products and review of strategic transactions and their impact on shareholder value. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2023 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.
Last Trade: | US$3.93 |
Daily Change: | -0.28 -6.65 |
Daily Volume: | 3,633 |
Market Cap: | US$5.340M |
August 13, 2024 May 09, 2024 November 09, 2023 |
GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...
CLICK TO LEARN MOREDevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORECOPYRIGHT ©2022 GREEN STOCK NEWS